StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38+0.00 (0.00%)

Close on Nov 18, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Inhibikase Therapeutics's operating margin for the twelve months ending Sep 30, 2024 was -2006393700.0%. For fiscal 2023 it was -7712.0%, against -14686.2% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-7712.0%+6974.2
FY2022Dec 31, 2022-14686.2%−14209.9
FY2021Dec 31, 2021-476.2%−72.7
FY2020Dec 31, 2020-403.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2023Dec 31, 2023-440356600.0%−440349780.4
Q3 FY2023Sep 30, 2023-5993.4%+55906.2
Q2 FY2023Jun 30, 2023-5328.1%+65489.1
Q1 FY2023Mar 31, 2023-7307.6%+2773.8
Q4 FY2022Dec 31, 2022-6819.6%−6626.8
Q3 FY2022Sep 30, 2022-61899.6%−61713.0
Q2 FY2022Jun 30, 2022-70817.1%−70112.5
Q1 FY2022Mar 31, 2022-10081.5%−8320.0
Q2 FY2021Jun 30, 2021-192.8%−4.3
Q1 FY2021Mar 31, 2021-186.6%+12.9
Q4 FY2020Dec 31, 2020-704.7%–
Q3 FY2020Sep 30, 2020-1761.4%–
Q2 FY2020Jun 30, 2020-188.5%–
Q1 FY2020Mar 31, 2020-199.4%–

More Inhibikase Therapeutics figures

See a number that looks wrong?